Investigational drug · Phase 3
M701
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Malignant Ascites.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "M701"
First trial start
2024
Mar 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "M701", any sponsor or status.
Conditions studied
As listed on its trial records.
- Malignant Ascites
Largest trials
Live from ClinicalTrials.gov: studies naming "M701" as an intervention, largest first.
- Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific AntibodyPivotal-lookingActive, not recruiting
Wuhan YZY Biopharma Co., Ltd.Industry
NCT06432296 · 312 participants · Start Mar 25, 2024 · Primary completion Aug 22, 2025
Drug: M701 · For: Malignant Ascites
Sites: Beijing, China; Harbin, China
- A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLCPivotal-lookingRecruiting
Wuhan YZY Biopharma Co., Ltd.Industry
NCT05543330 · 116 participants (planned) · Start Sep 30, 2022 · Primary completion Sep 15, 2026
Drug: M701 pleural infusion; Cisplatin pleural infusion · For: Malignant Pleural Effusions; NSCLC Stage IV
Sites: Hangzhou, China
- Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific AntibodyPivotal-lookingCompleted
Wuhan YZY Biopharma Co., Ltd.Industry
NCT06266091 · 115 participants · Start Nov 24, 2021 · Primary completion Feb 14, 2024
Drug: M701; paracentesis · For: Malignant Ascites
Sites: Beijing, China
Wuhan YZY Biopharma Co., Ltd.Industry
NCT04501744 · 35 participants · Start Sep 30, 2018 · Primary completion Feb 28, 2022
Drug: Cohort 1 of M701; Cohort 2 of M701 and 5 more · For: Malignant Ascites; Cancer
Sites: Beijing, China; Wuhan, China
Newest research
PubMed records naming it or its code names, newest first.
- Emerging innovative immunotherapies in malignant ascites: current landscape, challenges and perspectives.
Liu X, Peng X, Wu X, et al. · Front Oncol 2026
- Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors.
Liu R, Lin R, Li N, et al. · Exp Hematol Oncol 2025
- Single energy CT-based mass density and relative stopping power estimation for proton therapy using deep learning method.
Gao Y, Chang CW, Roper J, et al. · Front Oncol 2023
- Efficacy of Bispecific Antibody Targeting EpCAM and CD3 for Immunotherapy in Ovarian Cancer Ascites: An Experimental Study.
Li YN, Li YY, Wang SX, et al. · Curr Med Sci 2023
- Incremental Encoder Speed Acquisition Using an STM32 Microcontroller and NI ELVIS.
Pop AA · Sensors (Basel) 2022
- Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method.
Song L, Xue J, Zhang J, et al. · Eur J Pharm Sci 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.